Symbiosis Pharmaceutical Services, a small CMO located in Scotland, said it is offering a new bulk lyophilisation (freeze-drying) service after getting new contracts from the pharmaceutical industry.
The Sterling, Scotland-based company will use the process to support clients in the U.S., Europe and Asia to assist in the manufacturing of bulk intermediates and APIs by lyophilisation, Symbiosis said in a press release.
Though lyophilisation has been used at its facility before, the company now offers the ability to provide both aseptic and low bioburden clean room dispensing of bulk materials.
|Symbiosis CEO Colin MacKay|
"This service launch has very much been driven by market demand from biotech and pharmaceutical companies requiring either a one-off batch or the ongoing bulk lyophilisation of APIR or finished products," Colin MacKay, the company's CEO, said in a statement.
Symbiosis was among a number of other companies to open biologics plants in 2012 when Belgian drugmaker UCB Pharma completed an $84.8 million plant to manufacture products it had been outsourcing. Eisai subsidiary Morphotek earlier that year opened an $80 million plant in Exton, PA, that could produce multiple biologics simultaneously.
- check out the release